Abstract
Suicide events and episodes are serious human psychiatric disorders affected by a great number of different environmental/economic factors, early trauma/abuse, human bad living habits, human genomic properties and drug intervention decisions. In order to improve antidepressant therapeutics in clinics, the relationships between efficacy and toxicities of antidepressants have to be considered fundamentally. Since the occurrences and risks of suicidal events or episodes come from interplay between insiders (chemical/genomic/bioinformatics factors) and outsiders (economic/social/ previous trauma conditions and so on), new perspectives and scientific studies must be implemented for revealing these interrelated factors step-by-step and updating therapeutics in human beings. New paradigms and clinical strategies –joint-expert groups and clinical practices (a psychiatrist with other field specialists) should be established for individual patients in future. Thus can some improvements in clinical trials be achieved in a long run?
Keywords: Economic conditions, environmental factors, human genome, medicinal chemistry, neural toxicity, Psychiatric disorders.
Central Nervous System Agents in Medicinal Chemistry
Title:The Suicidal Risks and Treatments, Seek Medications from Multi-disciplinary
Volume: 16 Issue: 3
Author(s): Da-Yong Lu, Peng-Peng Zhu, Ting-Ren Lu and Jin-Yu Che
Affiliation:
Keywords: Economic conditions, environmental factors, human genome, medicinal chemistry, neural toxicity, Psychiatric disorders.
Abstract: Suicide events and episodes are serious human psychiatric disorders affected by a great number of different environmental/economic factors, early trauma/abuse, human bad living habits, human genomic properties and drug intervention decisions. In order to improve antidepressant therapeutics in clinics, the relationships between efficacy and toxicities of antidepressants have to be considered fundamentally. Since the occurrences and risks of suicidal events or episodes come from interplay between insiders (chemical/genomic/bioinformatics factors) and outsiders (economic/social/ previous trauma conditions and so on), new perspectives and scientific studies must be implemented for revealing these interrelated factors step-by-step and updating therapeutics in human beings. New paradigms and clinical strategies –joint-expert groups and clinical practices (a psychiatrist with other field specialists) should be established for individual patients in future. Thus can some improvements in clinical trials be achieved in a long run?
Export Options
About this article
Cite this article as:
Lu Da-Yong, Zhu Peng-Peng, Lu Ting-Ren and Che Jin-Yu, The Suicidal Risks and Treatments, Seek Medications from Multi-disciplinary, Central Nervous System Agents in Medicinal Chemistry 2016; 16 (3) . https://dx.doi.org/10.2174/1871524916666160210142734
DOI https://dx.doi.org/10.2174/1871524916666160210142734 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls
Current Psychiatry Reviews Neuroinflammation and Immunity: A New Pharmacological Target in Depression
CNS & Neurological Disorders - Drug Targets Biochemical Changes Evidenced in Alzheimer's Disease: A Mini-Review
Letters in Drug Design & Discovery Biologics and the Cardiovascular System: A Double-Edged Sword
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prevalence of Oral and Systemic Manifestations in Pediatric HIV Cohorts with and without Drug Therapy
Current HIV Research Drug Delivery Nanosystems in Glioblastoma Multiforme Treatment: Current State of the Art
Current Neuropharmacology Fighting Diabetes: Lessons from Xenotransplantation and Nanomedicine
Current Pharmaceutical Design Radiolabeled Nucleosides for Predicting and Monitoring the Cancer Therapeutic Efficacy of Chemodrugs
Current Medicinal Chemistry Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design On Epistasis: A Methodological Review for Detecting Gene-Gene Interactions Underlying Various Types of Phenotypic Traits
Recent Patents on Biotechnology Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Recent Updates on Current and Upcoming Biomarkers for Cardiovascular Diseases
Current Pharmaceutical Design Retinol-Binding Protein 4 and New Adipocytokines in Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Immuno-Isolation in Cancer Gene Therapy
Current Gene Therapy Meet Our Editorial Board Member
Letters in Drug Design & Discovery Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy